Skip to content
Log In
    All posts

    September 12, 2024 Customer Newsletter

    By   ·  2 minute read

    camping

    • Telemedicine Turmoil

    • Reasons to Subscribe 

    • Ban on Noncompetes

    • GPT-4 Boosts IR Health Literacy

    mindframe_picture_of_trees_in_summer_highly_detailed_happy_an_bf82c148-9766-4087-a8ea-8289b421bfa0_1Telemedicine - DEA Leaks, Direct-to-Consumer Competition, and DTC vs. Continuous Care Models

    It’s been a difficult few months for telemedicine. The rapid entry of pharmaceutical manufacturers, along with gyms, supplement retailers, and anyone else looking to profit from prescriptions, is creating havoc for physician practices trying to add essential services for their patients.

    A leak from the DEA reveals they are considering a controlled-substance rule, which is likely necessary. The rule would require an in-person visit before prescribing Class II substances. The last time they attempted this, they received 30,000 public comments. This development coincides with the expiration of COVID-era dispensations on telehealth prescriptions. 

    Pfizer and Eli Lilly were the first to launch direct-to-consumer prescriptions through telehealth services, but GlaxoSmithKline, Amgen, Merck, and Roche are all planning their own. All of these services offer discounts for using their platforms. We can’t think of a better way to disrupt continuity of care—congratulations. 

    And last, an article discusses the holistic model (continuous care with a primary care provider) versus the transactional model in telemedicine. Telemedicine is here to stay, and patients want it for certain types of services or interactions. If physicians and their associations don’t take the lead in guiding the process, we may end up with widespread self-management—and the next closest thing to self-prescription.

    Proposed DEA Rule Would Tighten Telehealth Prescriptions, According to Leak - Benefits Pro

    How to Stay Ahead of Direct-to-Consumer Telemedicine - Telehealth

    The Interaction Model vs. the Holistic Model in Telehealth - Medical Economics

    cust nl mindframe_picture_of_trees_in_summer_highly_detailed_happy_an_5625b150-428e-4f93-b8f4-612ee1ebb0a9_3

    4 reasons why

    cust nl mindframe_picture_of_mountains_in_summer_highly_detailed_happ_54c054ef-7b98-4b37-829d-4f86fee63fac_0-1A Federal Judge Struck Down FTC’s Ban on Noncompetes. What Does This Mean for Healthcare?

    A Texas district judge has, to the delight of hospital groups, struck down the FTC’s ban on noncompete agreements, ruling it both too broad and outside the FTC’s jurisdiction. The FTC is considering an appeal to the Fifth Circuit Court and has noted that it has a “unique test to weigh whether an entity is actually organized for the profit of the corporation or its members.” The ban did not apply to not-for-profits.

    A Federal Judge Struck Down FTC’s Ban on Noncompetes. What Does This Mean for Healthcare? - Medcity News
     

    cust nl mindframe_picture_of_trees_in_summer_highly_detailed_happy_an_bf82c148-9766-4087-a8ea-8289b421bfa0_2-1GPT-4 is Better at Explaining IR Procedures Than Physicians

    This is not at all surprising. The key strength of generative AI is its ability to compile summaries of stable knowledge bases at incredible speeds—and to converse with users about them endlessly, in over 21 languages, at any reading level, or even verbally. Patients may not always have access to doctors to ask all the questions they want, or they may be too intimidated by the healthcare process to ask questions. AIs are also likely better than humans at assessing a patient's understanding of the process.

    GPT-4 is Better at Explaining IR Procedures Than Physicians - Health Imaging

     

    Check out our latest blog article:  
    Subscribe To Our Blog And Save